Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

December 30, 2027

Conditions
Diabetic Foot Ulcers
Interventions
DRUG

Antimicrobial Peptide PL-5 Topical Spray and Placebo

Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.

Trial Locations (3)

33175

Bioresearch Partner Holdings, LLLP, Miami

33615

Santos Research Center, Corp, Tampa

92081

ILD Research Center, Vista

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.

INDUSTRY